NO982182L - Proteinkinase C-inhibitor - Google Patents

Proteinkinase C-inhibitor

Info

Publication number
NO982182L
NO982182L NO982182A NO982182A NO982182L NO 982182 L NO982182 L NO 982182L NO 982182 A NO982182 A NO 982182A NO 982182 A NO982182 A NO 982182A NO 982182 L NO982182 L NO 982182L
Authority
NO
Norway
Prior art keywords
inhibitor
protein kinase
kinase
protein
Prior art date
Application number
NO982182A
Other languages
English (en)
Other versions
NO310196B1 (no
NO982182D0 (no
Inventor
Gary Lowell Engel
Nagy Alphonse Farid
Margaret Mary Faul
Michael Robert Jirousek
Lori Aann Richardson
Jr Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO982182L publication Critical patent/NO982182L/no
Publication of NO982182D0 publication Critical patent/NO982182D0/no
Publication of NO310196B1 publication Critical patent/NO310196B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19982182A 1995-11-20 1998-05-13 Proteinkinase C-inhibitor, anvendelse av samme for fremstilling av medikament, farmasöytisk formulering omfattendesamme, fremgangsmåte for fremstilling av samme, samt forbindelsefor bruk som terapeutikum NO310196B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US697095P 1995-11-20 1995-11-20
PCT/US1996/018512 WO1997018809A1 (en) 1995-11-20 1996-11-18 Protein kinase c inhibitor

Publications (3)

Publication Number Publication Date
NO982182L true NO982182L (no) 1998-05-13
NO982182D0 NO982182D0 (no) 1998-05-13
NO310196B1 NO310196B1 (no) 2001-06-05

Family

ID=21723527

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982182A NO310196B1 (no) 1995-11-20 1998-05-13 Proteinkinase C-inhibitor, anvendelse av samme for fremstilling av medikament, farmasöytisk formulering omfattendesamme, fremgangsmåte for fremstilling av samme, samt forbindelsefor bruk som terapeutikum

Country Status (34)

Country Link
US (3) US5710145A (no)
EP (1) EP0776895B1 (no)
JP (1) JP3348859B2 (no)
KR (1) KR100304210B1 (no)
CN (1) CN1093759C (no)
AR (2) AR004717A1 (no)
AT (1) ATE172199T1 (no)
AU (1) AU711125B2 (no)
BR (1) BR9611724A (no)
CA (1) CA2237221C (no)
CO (1) CO4750823A1 (no)
CY (1) CY2103B1 (no)
CZ (1) CZ297524B6 (no)
DE (1) DE69600784T2 (no)
DK (1) DK0776895T3 (no)
EA (1) EA000967B1 (no)
EG (1) EG23871A (no)
ES (1) ES2122764T3 (no)
HU (1) HU226821B1 (no)
IL (1) IL124417A (no)
MX (1) MX9803792A (no)
MY (1) MY118068A (no)
NO (1) NO310196B1 (no)
NZ (1) NZ323571A (no)
PE (1) PE22798A1 (no)
PL (1) PL184715B1 (no)
RO (1) RO120074B1 (no)
SI (1) SI0776895T1 (no)
TR (1) TR199800759T2 (no)
TW (1) TW403754B (no)
UA (1) UA61897C2 (no)
WO (1) WO1997018809A1 (no)
YU (1) YU49315B (no)
ZA (1) ZA969646B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
KR100610127B1 (ko) * 1998-01-30 2006-08-09 다이소 가부시키가이샤 부탄트리올 유도체의 제조 방법
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6291446B1 (en) * 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
AU758241B2 (en) * 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
AU2001270252B2 (en) * 2000-07-03 2007-02-08 Catalent Pharma Solutions, Llc Expression vectors
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US6300106B1 (en) * 2000-11-22 2001-10-09 Ppg Industries Ohio, Inc. Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
AU2003241398A1 (en) * 2002-05-06 2003-11-17 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7232842B2 (en) * 2003-01-10 2007-06-19 Board Of Trustees Of The Leland Stanford Junior University Kinase inhibitors and associated pharmaceutical compositions and methods of use
DE602004025569D1 (de) 2003-06-18 2010-04-01 Tranzyme Pharma Inc Makrozyklische motilin rezeptorantagonisten
US20050152942A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
CN1964706A (zh) * 2004-03-17 2007-05-16 拉斯·M·拉森 通过抑制视觉周期预防视网膜病
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
WO2006068988A1 (en) * 2004-12-20 2006-06-29 Eli Lilly And Company Combination therapy for vascular complications associated with hyperglycemia
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US8508369B2 (en) 2006-09-01 2013-08-13 Intermec Ip Corp. RFID tag system with block coding, such as space-time block coding
AR069799A1 (es) * 2007-12-21 2010-02-17 Novartis Ag Composicion farmaceutica
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
WO2010098888A1 (en) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
CA2795456A1 (en) 2010-03-30 2011-10-06 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
RU2674995C2 (ru) 2012-11-29 2018-12-14 Новартис Аг Фармацевтические комбинации
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US20180185259A1 (en) 2016-12-19 2018-07-05 Chromaderm, Inc. Methods of treating hyperpigmentation disorders
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
KR20230005944A (ko) 2020-05-01 2023-01-10 어플라이드 테라퓨틱스 인크. 소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물
CA3255435A1 (en) 2022-05-20 2023-11-23 Dermbiont, Inc. Compositions and formulations allowing the use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
WO1994007895A1 (en) * 1992-09-25 1994-04-14 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
KR100340159B1 (ko) * 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
IL124417A (en) 2002-11-10
AU1054897A (en) 1997-06-11
US5710145A (en) 1998-01-20
PE22798A1 (es) 1998-05-11
EG23871A (en) 2007-11-27
NO310196B1 (no) 2001-06-05
JP3348859B2 (ja) 2002-11-20
HUP9903377A3 (en) 2000-04-28
KR19990067596A (ko) 1999-08-25
ATE172199T1 (de) 1998-10-15
YU49315B (sh) 2005-06-10
WO1997018809A1 (en) 1997-05-29
CZ150298A3 (cs) 1998-12-16
KR100304210B1 (ko) 2001-11-05
US6015807A (en) 2000-01-18
CO4750823A1 (es) 1999-03-31
IL124417A0 (en) 1998-12-06
RO120074B1 (ro) 2005-08-30
YU60996A (sh) 1999-03-04
BR9611724A (pt) 1999-06-01
EP0776895A1 (en) 1997-06-04
SI0776895T1 (en) 1999-04-30
CZ297524B6 (cs) 2007-01-03
ES2122764T3 (es) 1998-12-16
PL326754A1 (en) 1998-10-26
AU711125B2 (en) 1999-10-07
CN1202825A (zh) 1998-12-23
EA000967B1 (ru) 2000-08-28
NZ323571A (en) 1998-12-23
AR004717A1 (es) 1999-03-10
JPH11500149A (ja) 1999-01-06
ZA969646B (en) 1998-05-18
HUP9903377A2 (hu) 2000-02-28
DK0776895T3 (da) 1999-06-23
CA2237221C (en) 2003-03-25
HU226821B1 (en) 2009-11-30
AR004336A1 (es) 1998-11-04
MX9803792A (es) 1998-09-30
DE69600784D1 (de) 1998-11-19
PL184715B1 (pl) 2002-12-31
TW403754B (en) 2000-09-01
EP0776895B1 (en) 1998-10-14
TR199800759T2 (xx) 2001-01-22
UA61897C2 (en) 2003-12-15
US6117861A (en) 2000-09-12
MY118068A (en) 2004-08-30
DE69600784T2 (de) 1999-04-08
NO982182D0 (no) 1998-05-13
CY2103B1 (en) 2002-04-05
CA2237221A1 (en) 1997-05-29
EA199800374A1 (ru) 1998-10-29
CN1093759C (zh) 2002-11-06

Similar Documents

Publication Publication Date Title
DK0776895T3 (da) Proteinkinase C inhibitor
NO974453D0 (no) Proteinkinase C-hemmere
DE69435267D1 (de) Proteinkinase C Inhibitoren
FI945706A7 (fi) Proteiinikinaasi C-inhibiittoreita
DE69627179T2 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
NO992336D0 (no) Raf-kinase-inhibitorer
FI973492L (fi) NO-syntaasin estäjät
EP0841919A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
DE69323185D1 (de) Proteinkinase c-inhibitor
PT858464E (pt) Inibidores de trombina
DE69622983D1 (de) Chip-spule
DE69618742D1 (de) Schaltungsanordnung
PT863916E (pt) Tripeptidos de polifluoroalquil triptofano inibidores de trombina
DE69734817D1 (de) Neuartige amp-aktivierte proteinkinase
BR9610514A (pt) Inibidores cicloantihelmínticos
DE69619622D1 (de) Schaltungsanordnung
KR960033453U (ko) 건강음료 보약탕기
ITMI930345A0 (it) N-acil-peptidi inibitori delle protein-chinasi
KR970703937A (ko) 금속단백질 분해효소 억제제(Metallproteinase inhibitors)
FI950022A0 (fi) Eosinofiiliset kemotaksiainhibiittorit
KR970048502U (ko) 칩
ES1032844Y (es) Estanteria flotante
UA25624A (uk) Магhітооптичhа зчитувальhа головка
FI2187U1 (fi) Hoerndetalj till plaottlaoda

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees